Latest Conference Articles

The data presented at DDW show similar safety and efficacy for the 2 treatments.

Montefiore psychiatry chair Jonathan Alpert, MD, PhD, discusses suggested updates to the DSM-5—with consideration to social determinants and patient-reported functioning.

Recurrence commonly occurred during the first 2 weeks regardless of treatment.

Linda Chokroverty, MD, discusses the significance of timing, communication and care coordination when children are affected by disasters or trauma.

APA president-elect Rebecca W. Brendel, MD, JD, discusses the need to prepare for a "twin mental health pandemic" while continuing to appropriately facilitate innovations in psychiatric care.

Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.

Linda Chokroverty, MD, discusses the role psychiatrists play in managing the mental health effects of disasters, and how children specifically may be impacted.

Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.

A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.

The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.

There remains a need for longer-term observational studies comparing the 2 treatments.

It takes even more than a village to provide the comprehensive care needed for aging, neurocognitive patients, says Rajesh R. Tampi, MD, MS.

A 6-year mirror analysis of risperidone, once-monthly paliperidone palmitate or once-monthly aripiprazole concludes suggesting the regimens may serve as an alternative to clozapine.

Dr. Trudzinski speaks of the importance of diagnosing sex-specific pulmonary and extra-pulmonary comorbidities in women with COPD, as well as the lack of research regarding COPD prevalence in women.

Safety and efficacy data for the oral asthma therapy was presented at a late-breaking session at ATS 2022.

Investigators defined AHR as “a hallmark of persistent asthma”, noting that it could also be assessed via indirect challenge with mannitol.

In particular, airway epithelial cells (AEC) in allergic asthmatic (AA) were shown to upregulate mucus metaplasia, matrix-remodeling, and glycolytic programs while failing to upregulate antioxidant genes.

Results from the 2 APPaRENT trials suggest regular inhaled corticosteroids/LABA alone or with short-acting beta agonists were the preferred treatment approach with physicians.

With this new decade-long cohort, Dr. Chen notes that researchers are "one step closer to a more accurate view of what sarcoidosis may be like in the United States", with has been suggested to be more prominent in African American communities.

A post-hoc analysis of the VOYAGE study also found that the biologic improved the percent predicted pre-bronchodilator FEV1 in this patient population.

Dr. Richmond speaks to the newest pulmonology data from Vanderbilt University that was presented at ATS 2022.

Dr. Chatterjee cites an urgent need for new treatment strategies, adding that reducing airway iron could result in a decrease in the production of aspergillus fumigatus proteases.

Dr. Au spoke of how the new data provides an opportunity to think about how lifestyle intervention focused on weight and moderate exercise can actually have meaningful impacts on patients with COPD.

This model was responsible for correctly identifying 73% of patients with pulmonary arterial hypertension 6 months prior to a confirmed diagnosis.

Dr. Holly Keir cites "massive changes" in beta diversity following ICS withdrawals in patients with moderate to very severe COPD.

Dr. Lugogo explains how the ProAir Digihaler was used to accurately monitor SABA use in patients with asthma -many of whom were overusing their medication- which could allow clinicians to make appropriate changes to treatment.

The new study provides insights into the physiological factors for greater AtoOxy efficacy and can be referenced when identifying patients who are most suited for the therapy.

Investigators from this ATS session suggested THN therapy could be used to treat OSA, believing in to be “a simpler approach than incumbent technology with no sensor and an easier, proximal electrode implantation”.